RTRyan E. Temel

Ryan E. Temel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryan E. Temel has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Lawrence L. Rudel

    2 shared publications
  • Abraham K. Gebre

    1 shared publication
  • Allison L. McDaniel

    Department of Pathology-Section on Lipid Sciences, Wake Forest University School of Medicine, Winston-Salem, 27157, North Carolina, USA

    1 shared publication
  • Carlos Fernandez-Hernando

    Leon H. Charney Division of Cardiology, Department of Medicine, Marc and Ruti Bell Vascular Biology and Disease Program, New York University School of Medicine, New York, 10016, New York, USA

    1 shared publication
  • Christine C. Esau

    Regulus Therapeutics, San Diego, 92121, California, USA

    1 shared publication
  • Cynthia J. Lees

    Department of Pathology-Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, 27157, North Carolina, USA

    1 shared publication

Latest Publications

  • Open Access

    Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides

    by Katey J. Rayner, Christine C. Esau, Farah N. Hussain, Allison L. McDaniel, Stephanie M. Marshall, Janine M. van Gils, Tathagat D. Ray, Frederick J. Sheedy, Leigh Goedeke, Xueqing Liu, et al.

    Recent work in mice has shown that microRNA-33a is an important regulator of lipid metabolism and that its inhibition can increase plasma high-density lipoprotein (HDL) and decrease atherosclerosis. Rayner et al. take an important step in translating these findings to non-human primates (African green monkeys), which, like humans and unlike mice, express both miR-33a and miR-33b. They find that anti-miR-33 is effective at inhibiting both miR-33a and miR-33b. As seen in the mouse studies, anti-miR33 raised plasma HDL but had the additional beneficial effect of reducing very low-density lipoprotein triglycerides, making this type of 'antagomir' therapy a candidate method of treating dyslipidaemias that increase cardiovascular disease risk. Cardiovascular disease remains the leading cause of mortality in westernized countries, despite optimum medical therapy to reduce the levels of low-density lipoprotein (LDL)-associated cholesterol. The pursuit of novel therapies to target the residual risk has focused on raising the levels of high-density lipoprotein (HDL)-associated cholesterol in order to exploit its atheroprotective effects1. MicroRNAs (miRNAs) have emerged as important post-transcriptional regulators of lipid metabolism and are thus a new class of target for therapeutic intervention2. MicroRNA-33a and microRNA-33b (miR-33a/b) are intronic miRNAs whose encoding regions are embedded in the sterol-response-element-binding protein genes SREBF2 and SREBF1 (refs 3–5), respectively. These miRNAs repress expression of the cholesterol transporter ABCA1, which is a key regulator of HDL biogenesis. Recent studies in mice suggest that antagonizing miR-33a may be an effective strategy for raising plasma HDL levels3,4,5 and providing protection against atherosclerosis6; however, extrapolating these findings to humans is complicated by the fact that mice lack miR-33b, which is present only in the SREBF1 gene of medium and large mammals. Here we show in African green monkeys that systemic delivery of an anti-miRNA oligonucleotide that targets both miR-33a and miR-33b increased hepatic expression of ABCA1 and induced a sustained increase in plasma HDL levels over 12 weeks. Notably, miR-33 antagonism in this non-human primate model also increased the expression of miR-33 target genes involved in fatty acid oxidation (CROT, CPT1A, HADHB and PRKAA1) and reduced the expression of genes involved in fatty acid synthesis (SREBF1, FASN, ACLY and ACACA), resulting in a marked suppression of the plasma levels of very-low-density lipoprotein (VLDL)-associated triglycerides, a finding that has not previously been observed in mice. These data establish, in a model that is highly relevant to humans, that pharmacological inhibition of miR-33a and miR-33b is a promising therapeutic strategy to raise plasma HDL and lower VLDL triglyceride levels for the treatment of dyslipidaemias that increase cardiovascular disease risk.


  • A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport.

    by Ryan-E Temel, J-Mark Brown

    Reduction of low-density lipoprotein-cholesterol through statin therapy has only modestly decreased coronary heart disease (CHD)-associated mortality in developed countries, which has prompted the search for alternative therapeutic strategies for CHD. Major efforts are now focused on therapies that augment high-density lipoprotein (HDL)-mediated reverse cholesterol transport (RCT), and ultimately increase the fecal disposal of cholesterol. The process of RCT has long been thought to simply involve HDL-mediated delivery of peripheral cholesterol to the liver for biliary excretion out of the body. However, recent studies have revealed a novel pathway for RCT that does not rely on biliary secretion. This non-biliary pathway rather involves the direct excretion of cholesterol by the proximal small intestine. Compared to RCT therapies that augment biliary sterol loss, modulation of non-biliary fecal sterol loss through the intestine is a much more attractive therapeutic strategy, given that excessive biliary cholesterol secretion can promote gallstone formation. However, we are at an early stage in understanding the molecular mechanisms regulating the non-biliary pathway for RCT, and much additional work is required in order to effectively target this pathway for CHD prevention. The purpose of this review is to discuss our current understanding of biliary and non-biliary contributions to RCT with particular emphasis on the possibility of targeting the intestine as an inducible cholesterol secretory organ.


  • Diet Effects on Atherosclerosis in Mice

    by Ryan E. Temel, Lawrence L. Rudel

    The development of atherosclerosis in mice can be dramatically affected by the composition of the diet. The nutrients that seem to have the greatest impact on the atherosclerotic process in not only mice but also humans are fat and cholesterol. For this reason, many murine diets have been created that contain different levels of cholesterol and numerous types of fat. Typically, these diets cause the accumulation of atherogenic, apoB-containing lipoproteins in plasma and depending upon the severity of the hypercholesterolemia stimulate the formation of aortic atherosclerosis that often progresses from fatty streak lesions to advanced, fibrous plaques. In this review, we compare the abilities of diets enriched with various amounts of cholesterol and different types of saturated, monounsaturated, and polyunsaturated fats to promote atherosclerosis in an assortment of mouse models. In addition, we make recommendations concerning the utilization of these diets to promote atherosclerotic lesion formation in mice.